Related Experiment Video
Updated: Feb 17, 2026

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
Published on: June 9, 2017
A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy
Chuanzhen Yang1,2, Weicheng Zang1,2, Zefang Tang3
1State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China.
Abstract:
A competent DNA damage response (DDR) helps prevent cancer, but once cancer has arisen, DDR can blunt the efficacy of chemotherapy and radiotherapy that cause lethal DNA breakage in cancer cells. Thus, blocking DDR may improve the efficacy of these modalities. Here, we report a new DDR mechanism that interfaces with inflammatory signaling and might be blocked to improve anticancer outcomes. Specifically, we report that the ubiquitin-editing enzyme A20/TNFAIP3 binds and inhibits the E3 ubiquitin ligase RNF168, which is responsible for regulating histone H2A turnover critical for proper DNA repair. A20 induced after DNA damage disrupted RNF168-H2A interaction in a manner independent of its enzymatic activity. Furthermore, it inhibited accumulation of RNF168 and downstream repair protein 53BP1 during DNA repair. A20 was also required for disassembly of RNF168 and 53BP1 from damage sites after repair. Conversely, A20 deletion increased the efficiency of error-prone nonhomologous DNA end-joining and decreased error-free DNA homologous recombination, destablizing the genome and increasing sensitivity to DNA damage. In clinical specimens of invasive breast carcinoma, A20 was widely overexpressed, consistent with its candidacy as a therapeutic target. Taken together, our findings suggest that A20 is critical for proper functioning of the DDR in cancer cells and it establishes a new link between this NFκB-regulated ubiquitin-editing enzyme and the DDR pathway.Significance: This study identifies the ubiquitin-editing enzyme A20 as a key factor in mediating cancer cell resistance to DNA-damaging therapy, with implications for blocking its function to leverage the efficacy of chemotherapy and radiotherapy. Cancer Res; 78(4); 1069-82. ©2017 AACR.
Insights
The ubiquitin-editing enzyme A20 inhibits DNA repair, promoting cancer cell resistance to chemotherapy. Blocking A20 may enhance cancer treatment efficacy by improving DNA damage response.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- A functional DNA damage response (DDR) is crucial for preventing cancer.
- However, in established cancers, DDR can reduce the effectiveness of DNA-damaging therapies like chemotherapy and radiotherapy.
- Targeting DDR pathways presents a strategy to enhance anticancer treatment outcomes.
Purpose of the Study:
- To investigate a novel DDR mechanism involving the ubiquitin-editing enzyme A20/TNFAIP3.
- To determine if blocking this A20-mediated pathway can improve anticancer therapy efficacy.
- To establish the link between A20, DDR, and inflammatory signaling in cancer.
Main Methods:
- Investigated the interaction between A20 and the E3 ubiquitin ligase RNF168.
- Assessed the role of A20 in regulating histone H2A turnover and DNA repair protein localization (RNF168, 53BP1) after DNA damage.
- Utilized A20 deletion models to evaluate effects on DNA repair pathways (NHEJ, HR) and DNA damage sensitivity.
- Analyzed A20 expression in clinical breast carcinoma specimens.
Main Results:
- A20 directly binds and inhibits RNF168, a key regulator of histone H2A turnover for DNA repair.
- A20 disrupts the RNF168-H2A interaction and inhibits RNF168/53BP1 accumulation at DNA damage sites.
- A20 is essential for the disassembly of RNF168 and 53BP1 post-repair.
- A20 deficiency enhances error-prone DNA repair (NHEJ), destabilizes the genome, and increases sensitivity to DNA damage.
- A20 is overexpressed in invasive breast carcinoma, suggesting its therapeutic potential.
Conclusions:
- A20 plays a critical role in the DNA damage response within cancer cells.
- A20 establishes a novel connection between NFκB-regulated inflammatory signaling and the DDR pathway.
- A20 functions as a mediator of cancer cell resistance to DNA-damaging therapies, making it a potential therapeutic target.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Abnormal Proliferation
Treatment Resistant Cancers
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway

